1 The EIC Accelerator Project

Overview of the EIC Accelerator Program

The European Innovation Council (EIC) Accelerator program is a pivotal financial instrument designed to support small and medium-sized enterprises (SMEs) and startups in Europe. The primary objective of the EIC Accelerator is to foster innovation by providing funding and resources to high-potential companies, particularly in the DeepTech sector, which includes advanced technologies that require significant research and development.

Funding Structure

The EIC Accelerator offers a unique funding model that encompasses both grants and equity investments. The grant component can provide up to €2.5 million to cover specific project-related costs, particularly in the prototyping and testing phases. This grant is instrumental in reducing the financial burden on innovative companies, allowing them to focus on developing their technologies.

In addition, the EIC Accelerator also offers equity financing, which can amount to up to €15 million until 2024 and is set to decrease to €10 million from 2025 onward. This equity component is designed to help companies scale effectively, enabling them to attract further investments from private sector stakeholders. The dual funding approach allows companies not only to advance their technological innovations but also to enhance their market readiness and competitiveness.

Purpose in the European Ecosystem

The EIC Accelerator plays a crucial role in the European startup and DeepTech ecosystem by bridging the funding gap that often exists in the early stages of innovation. By providing financial resources, mentorship, and networking opportunities, the program helps companies navigate the complexities of bringing groundbreaking technologies to market. This support is especially vital for startups that may struggle to secure traditional funding due to the high-risk nature of their projects.

Furthermore, the EIC Accelerator fosters collaboration between startups and established industry players, facilitating knowledge transfer and promoting innovative solutions that address societal challenges.

Scaling and Private Sector Funding

The EIC Accelerator serves as a catalyst for scaling operations by equipping companies with the necessary tools and resources to attract additional private sector funding. The program not only provides initial financial support but also enhances the credibility of the startups within the investment community. By demonstrating a commitment to innovation and having the backing of the EIC, companies can significantly increase their chances of attracting venture capital and other forms of private investment.

Case Study: VALUEBIOTECH SRL and the M.I.L.A.N.O. Robot

Company Overview

VALUEBIOTECH SRL, based in Italy, is an innovative company that has made significant strides in the medical technology field. The company aims to revolutionize surgical procedures, enhancing patient care and outcomes through advanced technological solutions.

Project Details: M.I.L.A.N.O. Robot

The project, known as M.I.L.A.N.O. (Minimally Invasive Laparoscopic Assistant for Needle Operations), focuses on transforming everyday surgical experiences into painless and scarless procedures. This project stems from a growing need to minimize the physical and emotional impact of surgical interventions on patients. With a submission date of October 5, 2022, for the Step 2 proposal, VALUEBIOTECH SRL successfully advanced through the EIC Accelerator program and secured funding after their Step 3 interview.

Technology Basics and Background

The M.I.L.A.N.O. Robot incorporates cutting-edge robotics and minimally invasive techniques to assist surgeons in performing needle operations with greater precision and reduced discomfort. Traditional surgical methods often involve larger incisions, leading to increased pain, longer recovery times, and noticeable scarring. In contrast, the M.I.L.A.N.O. Robot utilizes advanced imaging and robotic guidance to perform procedures through smaller incisions, thereby enhancing patient comfort and reducing recovery time.

The technology is built on principles of robotic surgery, which combines mechanical engineering, software algorithms, and medical expertise. By integrating real-time imaging and machine learning, the M.I.L.A.N.O. Robot can adapt to varying surgical environments and patient anatomies, ensuring optimal outcomes.

The anticipated impact of this innovation extends beyond patient comfort; it is expected to reduce healthcare costs associated with post-operative care, minimize the risk of complications, and ultimately improve surgical success rates.

Conclusion

In summary, the EIC Accelerator program plays a vital role in fostering innovation within the European startup ecosystem, particularly for DeepTech firms like VALUEBIOTECH SRL. By providing a comprehensive funding structure that includes both grants and equity, the program enables groundbreaking companies to develop technologies that address critical challenges in healthcare and beyond. The M.I.L.A.N.O. Robot exemplifies this mission, offering a transformative solution that promises to enhance surgical procedures and improve patient outcomes.

2 The Funding Rounds

Financing Raised by VALUEBIOTECH SRL

VALUEBIOTECH SRL, an Italian medtech company known for its M.I.L.A.N.O. Robotic Platform, has raised capital through a combination of grants and private investment since its founding.

Funding Rounds and Timing

• March 2015: The company received a €50,000 grant from the European Innovation Council (EIC).
• 2021: Azimut Holding joined as an investor. This involvement provided VALUEBIOTECH with resources to expand its team and advance development and certification processes.
• October 2022: VALUEBIOTECH was awarded a €2.5 million grant by the EIC Accelerator following their successful application in October 2022. This funding round marked the largest publicly documented capital raise for the company.
• The total reported funding for VALUEBIOTECH is approximately €2.6 million (about $60,240 according to some sources; however, this figure appears inconsistent with others that cite euros in millions).

Investors

• European Innovation Council – Provided both early stage (€50k) and later (€2.5m) non-dilutive grant funding.
• Azimut Holding – Joined as an equity investor in 2021, supporting organizational growth and product development.
• Other investors are alluded to on their website but are not named individually; it is stated that "many investors have believed in us" since 2012.

Company Valuations

No public information is available regarding specific company valuations at any stage of investment or following EIC Accelerator support.

Exit Events: IPOs or Acquisitions

There are no records or reports of IPOs (Initial Public Offerings), buyouts, or acquisitions involving VALUEBIOTECH SRL up to May 2025.

Summary Table: Funding Timeline & Details

Date	Funding Type	Amount	Investor/Source
Mar 2015	Grant	€50k	European Innovation Council
2021	Equity Investment	Undisclosed	Azimut Holding
Oct 2022	Grant	€2.5m	EIC Accelerator

Additional Information Related to Funding Rounds

The October 2022 award was part of one of the most competitive rounds under Horizon Europe’s EIC Accelerator program; recipients generally receive funds within three months post-selection. The bulk of recent financing stems from EU innovation programs rather than traditional venture capital or large institutional backers.

No evidence exists indicating subsequent funding rounds after October 2022 nor any significant disclosures about valuation increases resulting from these investments.

---

Sources:

• Valuebiotech Srl company information, funding & investors - Dealroom
• Valuebiotech Srl company information, funding & investors - New York State
• Valuebiotech Srl company information - Dealroom Hungary
• Investors - Valuebiotech
• ValueBiotech S.R.L. Company Information - Seedtable

3 The Press Releases

Valuebiotech SRL: Insights Post-EIC Accelerator Funding

Overview

Valuebiotech SRL, an Italian company, won the EIC Accelerator funding in October 2022. The company is renowned for its modular surgical robotic platform designed to make surgery more accessible and less invasive.

Technology and Mission

Valuebiotech focuses on transforming everyday surgery into a painless and scarless experience. Their modular robotic platform aims to democratize access to advanced surgical technologies, making them easier to use and more widely available.

Funding and Recognition

In October 2022, Valuebiotech was one of the 78 companies selected for funding by the European Innovation Council (EIC) Accelerator. The company received funding under the "Grant-first" financing type, which was the second most awarded type in that cut-off. This recognition underscores the company's innovative approach to healthcare technology.

Press Releases and Updates

Valuebiotech has highlighted their achievement in winning the EIC Accelerator funding on their website. They emphasize the significance of this award as a testament to Italian innovation and their commitment to advancing surgical technologies.

Partnerships and Team Updates

While specific details on partnerships or team updates are not mentioned in the available press releases or updates, the company's involvement in the EIC Accelerator suggests a strong network within the European innovation ecosystem.

Patents and Intellectual Property

There is no specific mention of new patents filed or granted to Valuebiotech in the available information. However, their participation in the EIC Accelerator indicates ongoing innovation and development efforts.

Social Media and Website Presence

Valuebiotech maintains a presence on their website, where they share news and updates about their achievements. However, detailed press releases or updates on social media platforms are not widely documented in the available information.

Conclusion

Valuebiotech SRL has made significant strides in the field of surgical robotics, highlighted by their success in securing EIC Accelerator funding. Their focus on making surgery more accessible and less invasive positions them well in the healthcare technology sector.

Sources

• EIC Accelerator winners and statistics October 2022
• News - Valuebiotech
• Valuebiotech Srl company information, funding & investors

4 The Technology Advancements

Valuebiotech SRL, an Italian medical device company, focuses on developing advanced robotic surgical tools aimed at enabling painless and scar-free surgery. Their flagship technology is the M.I.L.A.N.O. Robotic Platform, designed to allow surgeons to operate through a single incision or natural orifices without visible scarring. The platform integrates into operating rooms with an emphasis on improving the surgical experience for both patients and surgeons by enhancing precision and reducing invasiveness.

Since receiving EIC Accelerator funding on October 5, 2022, Valuebiotech has continued advancing its core technology with goals around innovation in surgical robotics that prioritize patient comfort and efficiency in hospital settings. The company’s website highlights their commitment to revolutionizing surgery by integrating surgeon skill with robotic assistance, suggesting ongoing development rather than a static product line.

Regarding advancements post-funding:

• Technological improvements or new features: While publicly detailed technical updates since the funding date are limited in open sources, Valuebiotech’s investor page emphasizes continuous innovation supported by strategic investments starting from 2012 onward. Azimut Holding's investment since 2021 has helped expand their team and plan certification steps of their robotic platform—indicating progress toward regulatory approval and enhanced capabilities.
• Market demonstrations or pilots: There is no explicit public information confirming clinical trials or commercial deployment of the M.I.L.A.N.O. Robotic Platform after receiving EIC funding as of now. However, given the company's focus on hospital efficiency and economic sustainability alongside engineering innovations for care services mentioned on their site, it is likely they are working towards demonstrations or pilot phases within clinical environments soon if not already underway.
• Intellectual property filings or scientific publications: No direct references were found about new patents filed by Valuebiotech after October 2022 nor recent scientific studies or whitepapers published under their name available publicly. Historically though, as part of Italy’s innovative medical device ecosystem referenced among top companies in Italy's health tech sector (including Valuebiotech), patent activity would be expected but specific updates post-EIC funding remain undisclosed online.

In summary:

Aspect	Status/Details
Core capability	Modular robotic surgical platform enabling scar-free surgery via single incision/natural routes
Post-EIC technological progress	Ongoing innovation; expanded development team; planning certification steps
Market demonstration	No confirmed public reports of clinical trials/pilots yet but preparing for implementation
Patents/publications	No recent patent filings/publications announced publicly

Valuebiotech continues to position itself as a promising innovator in minimally invasive robotic surgery with support from investors including Azimut Holding facilitating further development beyond their initial EIC Accelerator grant award.

Sources:

• Valuebiotech official website
• Investors page - Valuebiotech
• Top Medical Device Companies Italy - EU Startups

5 The Partnerships and Customers

VALUEBIOTECH SRL's Strategic Partnerships and Market Positioning Post-EIC Accelerator Funding

Since securing EIC Accelerator funding in October 2022, VALUEBIOTECH SRL has focused on advancing its M.I.L.A.N.O. Robotic Platform through collaborative partnerships and academic alliances. While specific customer names remain undisclosed publicly, the company’s growth strategy emphasizes technology-driven collaborations in surgical robotics and AI integration.

Key Partnerships and Collaborative Projects

VALUEBIOTECH maintains national and international partnerships with companies aligned with its mission to deliver "painless, scar-free surgery for everyone". These relationships focus on enhancing robotic-assisted surgical capabilities, particularly in minimally invasive abdominal and thoracic procedures.

A notable collaboration includes a joint initiative with the University of Trento (UniTN) to develop AI-driven imaging algorithms for multispectral vision systems. This project aims to improve intraoperative anatomical visualization by integrating sensors for fluorescence, time-of-flight (TOF), and spectral imaging into miniaturized robotic components (~1 cm scale). The partnership strengthens VALUEBIOTECH’s R&D pipeline while bridging clinical engineering expertise with academic innovation.

Technological Advancements from Collaborations

• Augmented Imaging: UniTN researchers are developing AI models to superimpose multiple imaging modalities (e.g., fluorescence-guided contrast agents) onto real-time surgical visuals, addressing limitations in current robotic perception systems.
• Miniaturization Expertise: Collaborative engineering efforts target device miniaturization without compromising functionality—a critical requirement for expanding applications in pediatric or confined anatomical regions.

Market Positioning via Partnerships

By aligning with academic institutions like UniTN, VALUEBIOTECH solidifies its role as an innovator in next-generation surgical robotics. The M.I.L.A.N.O. platform’s emphasis on multispectral imaging differentiation positions it competitively against larger players focusing solely on traditional robotic-assisted surgery techniques. Additionally, partnerships likely facilitate regulatory navigation through shared clinical validation frameworks across geographies.

While no new commercial partners are explicitly named post-2022 EIC funding period ended October 5th that year), VALUEBIOTECH’s existing network appears strategically retained to support scaling manufacturing capabilities while prioritizing R&D milestones tied to EU grants like Horizon Europe programs implied by their EIC affiliation). Their model mirrors industry trends where cross-sector alliances accelerate translational research into market-ready solutions—particularly vital given rising demand for cost-effective minimally invasive technologies globally).

---

Sources

• Partners - Valuebiotech
• Painless, scar-free surgery for everyone - Valuebiotech
• Reserved topic scholarships - 2023

6 The Hiring and Company Growth

VALUEBIOTECH SRL: Team Dynamics and Growth Post-EIC Accelerator Funding

Team Composition and Growth: VALUEBIOTECH’s leadership includes Antonello Forgione (Founder/CEO, MD PhD MBA FACS), supported by Marta Rossi Racagni (Business Developer) and Martina De Landro (Clinical Development Engineer). While the exact current headcount is undisclosed, their team is described as "dynamic and ambitious", focusing on surgical robotics innovation.

Hiring Activity: Public hiring data post-2022 EIC Accelerator win remains limited, but the company emphasizes collaboration with professionals who share their mission of improving surgical outcomes. Their EU-funded project (Transforming everyday surgery into a painless and scarless experience) runs until September 2025, suggesting ongoing recruitment for technical roles.

Strategic Scaling: Recent collaborations include a 2021 equity transaction where Sunrise Medical Technology acquired a 5.3% stake, though no post-2022 management changes are reported. The team’s focus on accessibility, cost efficiency, and modular robotic platforms implies hires in engineering and commercialization roles to support market expansion.

---

Sources

• Valuebiotech Team
• Valuebiotech Mission
• EU Project Details
• Sunrise Medical Stake Acquisition

7 The Media Features and Publications

Valuebiotech SRL: An Overview

Valuebiotech SRL, an Italian company, has made significant strides in the field of surgical robotics since receiving the EIC Accelerator funding on October 5, 2022. The company focuses on developing modular surgical robotic platforms designed to make surgeries painless and scar-free, accessible to a broader audience.

Media Features and Publications

While there is limited specific media coverage directly naming Valuebiotech SRL in major publications, the company's innovative approach to surgical robotics aligns with the growing interest in minimally invasive surgical technologies. Their modular platform is designed to enhance both the surgeon's and patient's experience across various hospital settings.

Content from Publications

The available content highlights Valuebiotech's mission to revolutionize surgical procedures by providing easy-to-use, modular robotic solutions. This approach aims to improve patient outcomes by reducing recovery time and enhancing surgical precision.

Podcasts or Interviews

There are no specific podcasts or interviews featuring Valuebiotech SRL's team members available in the public domain as of now.

Conference and Fair Visits, Presentations, or Participations

Valuebiotech's involvement in conferences and fairs is not extensively documented in the available sources. However, their participation would likely focus on showcasing their modular surgical robotic platforms to medical professionals and industry stakeholders.

Involvement in Events

Given the company's focus on innovative surgical solutions, their involvement in events would likely include medical technology conferences, where they could demonstrate their cutting-edge robotic systems and engage with potential partners and investors.

EIC Accelerator Funding

Receiving the EIC Accelerator funding has been a pivotal moment for Valuebiotech, providing them with the resources to further develop and commercialize their modular surgical robotic platform. This funding supports their goal of making painless and scar-free surgeries accessible globally.

---

Sources:

• Valuebiotech
• Team - Valuebiotech
• Valuebiotech Srl company information
• M.I.L.A.N.O. ROBOTIC PLATFORM